BioCentury
ARTICLE | Clinical News

Priority Review for AbbVie endometriosis therapy elagolix

November 3, 2017 4:52 AM UTC

FDA accepted and granted Priority Review to an NDA for elagolix (ABT-620, NBI-56418) from AbbVie Inc. (NYSE:ABBV) for the management of endometriosis with associated pain. Its PDUFA date is in 2Q18...

BCIQ Target Profiles

GnRH/LHRH receptor